• San Antonio: 210-874-2615
  • Nationwide Toll Free: 866-517-5659
  • Austin: 512-520-0221
  • Corpus Christi: 361-254-7873

Amputation Black Box Warning Shines New Light on Invokana Lawsuits

Janssen Pharmaceutical, Inc. is likely to see an influx of new lawsuits as the U.S. Food and Drug Administration (FDA) decides to require a Black Box warning addressing an increased risk of foot and leg amputations associated with the Type 2 diabetes drug Invokana.

Invokana Patients Twice As Likely to Require Amputation

The FDA’s decision follows findings by two clinical studies that determined patients taking canagliflozin, marketed as Invokana and Invokamet, were about twice as likely to require leg and foot amputation compared to patients taking a placebo.

An FDA safety communication released last month reveled that amputations of the toe and middle of the foot were most common; however, the release also  cited instances of amputation involving the leg, below and above the knee, and instances of patients requiring multiple amputations, sometimes involving both legs.

In one of the studies, Canagliflozin Cardiovascular Assessment Study (CANVAS), researchers noted that rates of amputation were as high as 7 out of every 1,000 patients treated with canagliflozin – more than double the 3 out of every 1,000 rate recorded among patient receiving a placebo.

This is the latest post-market warning to be added to Invokana by the FDA, with a kidney damage warning being added in June of 2016 and a diabetic ketoacidosis being added in 2015

Other Side Effects Associated with Invokana

Other adverse events reported by patients taking Invokana include:

  • Dehydration
  • Yeast infection
  • Hypotension
  • Ketoacidosis
  • Kidney injury and renal impairment
  • Hyperkalemia
  • Serious urinary tract infections
  • Bone fractures
  • Death

Contact Us for a Free Case Review


Contact Form
Do you really want to end conversation?
chat-icon Live chat
avatar Waiting